ALEC Alector, Inc.
Financings ·
Alector priced 36,600,000 shares at $2.05 for $75,030,000 gross. Its 2025 revenue fell to $21.0 million and cash used in operations was $184.0 million, against $59.9 million of cash on June 30, 2026.
Alector expects $7.7 million in restructuring charges and reports a preliminary $291.1 million in cash and short-term investments at September 30, 2025. Its head of research and development is resigning.
The company says the cut affects about 25 employees and will cost about $2.4 million. It still says cash lasts through 2026, while its lead frontotemporal dementia trial has yet to report and its term loan is secured on substantially all assets.
Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its work is informed by disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. A key component of its strategy is the Alector Brain Carrier platform, a proprietary blood-brain barrier delivery technology designed to improve central nervous system exposure to antibodies, enzymes and siRNA therapeutics at clinically practical doses. Its portfolio includes nivisnebart, formerly AL101 or GSK4527226, an investigational progranulin-elevating antibody. The company is also investing in biomarkers and biomarker assays to guide patient selection, demonstrate target and pathway engagement, and assess biological impact in the clinic. Its programs focus on genetically validated targets, supported by expertise in drug development, protein engineering and antibody discovery. The company says it relies on third parties to conduct clinical trials and to manufacture its product candidates.
| Product or program | What it is | Stage |
|---|---|---|
| Nivisnebart (formerly AL101 or GSK4527226) | Investigational progranulin-elevating antibody for neurodegenerative disease | |
| Alector Brain Carrier (ABC) platform | Blood-brain barrier delivery technology for antibodies, enzymes and siRNA |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $21.0 million | $100.6 million |
| Research and development | $123.1 million | $185.9 million |
| Net income (loss) | -$142.9 million | -$119.0 million |
| Cash from operations | -$184.0 million | -$229.9 million |
| Cash and equivalents | $65.8 million | $33.0 million |
| Short-term investments | $190.2 million | $380.4 million |
Our latest story on this, dated Oct 16, 2026: "Alector prices $75,030,000 stock offering at $2.05, above prior close". The story links the filing or release it is based on. Read the story.
Alector, Inc. trades under the ticker ALEC on NASDAQ.
Alector, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0Z2; LS:A2PCBM; LSX:A2PCBM.
The SEC Central Index Key (CIK) for Alector, Inc. is 1653087. Its filings are on SEC EDGAR.
111,656,919 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Alector, Inc. under United States.
Our directory classifies Alector, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Alector, Inc. is US0144421072.
aibio.space lists Alector, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its work is informed by disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption.
Nivisnebart (formerly AL101 or GSK4527226): Investigational progranulin-elevating antibody for neurodegenerative disease
Alector Brain Carrier (ABC) platform: Blood-brain barrier delivery technology for antibodies, enzymes and siRNA
$21.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Alector, Inc. reported a net loss of $142.9 million for the fiscal year ended Dec 31, 2025, and used $184.0 million of cash in operations, per its annual report to the SEC.
$123.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio